BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Home > article

State researchers transfer candidate material for COVID-19 treatment to LegoChem

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : June 9, 2020, 13:45 | Updated : June 9, 2020, 13:45
  • 트위터
  • 페이스북
  • 웨이보

[Yonhap Photo]

SEOUL -- A state-funded virus research group transferred a candidate material for COVID-19 treatment to LegoChem Biosciences, a domestic biopharmaceutical company that will push for the development of a new drug because it is less toxic and more effective than remdesivir, an antiviral medication approved in South Korea.

LegoChem signed a technology transfer agreement with the CEVI (new virus) Convergence Research Group involving eight government-funded research institutes led by the Korea Research Institute of Chemical Technology that has studied new virus diagnosis, vaccine development, treatment technologies.

Originally, the group has developed a candidate substance for the treatment of MERS, but animal testing showed it was 50 times more effective than remdesivir developed by Gilead Sciences and introduced the treatment of serious COVID-19 patients in South Korea.

"It is considered highly likely to be developed as a new drug due to its very good substance and low toxicity," CEVI Convergence Research Group head Kim Beom-tae said. LegoChem was optimistic saying it would quickly enter clinical trials to develop treatments that work for mutating viruses.

The research group transferred a synthetic antigen vaccine candidate with high ability to produce neutralizing antibodies to HK inno.N.

South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year. Researchers have been involved in quick experiments to check the efficacy of various drugs. For a short-term task, GC Pharma, a biotech company, has been involved in the development of GC5131A, an immunoglobulin drug based on plasma containing antibodies.

 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Health officials heave sigh of relief at early introduction of Novavax vaccine .
    Health officials heave sigh of relief at early introduction …
  • .Syringes for COVID-19 vaccines added to list of K-quarantine technologies.
    Syringes for COVID-19 vaccines added to list of 'K-quarantin…
  • .Semiconductor-based fast test kit using saliva able to debut in March: science minister.
    Semiconductor-based fast test kit using saliva able to debut…
  • .Russias Sputnik vaccine draws attention ahead of new CMO deal in S. Korea.
    Russia's Sputnik vaccine draws attention ahead of new CMO de…
  • .Kimchi refrigerator maker develops portable ultra-low temperature freezer for vaccines.
    Kimchi refrigerator maker develops portable ultra-low temper…

Real Time Photo News

  • .Girl band (G)I-DLE shrinks size to five members after school bullying controversy.

    Girl band (G)I-DLE shrinks size to five members after school bullying controversy

  • .Singer-actress IU reveals release schedule for album LILAC.

    Singer-actress IU reveals release schedule for album 'LILAC'

  • .S. Korea to build state-run K-pop concert hall for unaffordable online performances .

    S. Korea to build state-run K-pop concert hall for unaffordable online performances

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

Latest News

more+

  • Young woman faces trial for eating hamberger and insulting train passenger
  • Girl band (G)I-DLE shrinks size to five members after school bullying controversy
  • S. Korean companies to build combined cycle power plant in Thailand
  • Transparent LED film displays videos and images at official venue of Busan film festival
  • Daredevil surfers to be fined for ignoring storm warning
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view